Positive Data from Endometrial Cups Study with Settle® Presented at International Symposium
Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.
MCWF (Amplimune) Offers an Alternative for Herd Health as FDA Further Restricts Antibiotics
Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.
NovaVive offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency.
U.S. Study Demonstrates Positive Effect of Settle® on Endometrial Cups
Data from a study conducted by Gluck Equine Research Center (UKY) and Rood & Riddle Equine Hospital has demonstrated efficacy of Settle® to treat endometrial cups in mares. No other treatment has been found effective to date.
Feedlot Safety Study with Amplimune® Published in the Australian Veterinary Journal
A paper has been published in the Australian Veterinary Journal, “The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle”, summarizing a research study conducted by CSIRO.
MCWF (Amplimune) Significantly Improves Fertility and Decreases Clinical Mastitis and Metritis in Organic-Certified Dairy Herd
In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.